The effect of alloxan-induced diabetes on tissue plasminogen activator activity and plasmin inhibition in the rat

Self Cite

In a strain of genetically hypercholesterolemic rats (RICO), developed from an albino mutant of Rattus norvegicus (Sprague-Dawley, Tif: RAIf, SPF) by selective breeding, the intimal plasminogen activator activity (PAA) at the nonbranching regions of the aorta was markedly lower than at the nonbranching regions of the aorta in the control strain (Sprague-Dawley). At the branching regions of the aorta the intimal PAA showed no difference between the two strains of rats. In another strain of rats (HBC; hyper-beta-cholesterolemic) with a slightly elevated level of total cholesterol in the blood, a high concentration of LDL-cholesterol and a low concentration of triglycerides, the intimal PAA showed no difference from that in the control strain (Sprague-Dawley) at the branching and nonbranching regions of the aorta. 6 weeks after a single injection of streptozotocin at a diabetogenic dose (45 mg/kg) into RICO rats and the control strain, the intimal PAA was found to be increased by 280% in RICO rats, but only by 140% in controls, compared to that in the corresponding nontreated rats.

Section: Discussionsupporting

confidence: 77%

“…Streptozotocin could directly or indi rectly affect the intimal PAA. Biochemical and histological changes induced by experi mental diabetes might influence the intimal PAA [16]. Streptozotocin as a mutagenic fac tor [19] could also affect tissue PAA.…”

Section: Discussionmentioning

confidence: 99%

Plasminogen Activator Activity in the Aorta of Strains of Rats with Genetically Determined Different Patterns of Lipids in the Blood

Smokovitis

Auerswald

Müller

et al. 1982

Self Cite

“…To clarify the variations in fibrinolysis, some investigators have studied diabetes in ani mal models and reported increased activity of fibrinolysis, especially tissue plasmino gen-activator [20][21][22], However, no atten tion has been paid to fibrinolytic activity other than the plasmin system.…”

Section: Discussionmentioning

confidence: 99%

“…Although the biological significance of the enzyme re mains unclear, it seems likely that the en zyme may serve as a fibrin removing system acting in concert with plasmin. Enhanced plasminogen-activator activity has been re ported in diabetic rats induced by alloxan [9,21] and streptozotocin (STZ) [22], although no attention has yet been paid to fibrinolysis other than the plasmin system. This paper deals with the fibrinolytic activity of non plasmin protease and plasminogen-activator in diabetic rats induced by STZ.…”

Section: Introductionmentioning

confidence: 99%

Increase of Nonplasmin Fibrinolytic Activity in the Lung and Spleen of Streptozotocin-Induced Diabetic Rats

Okamoto

Nagamatsu

Yamamoto

et al. 1987

In streptozotocin-induced diabetes in rats, nonplasmin fibrinolytic activity was found to be significantly increased in the lung and spleen, but not in the liver and kidney. The plasminogen-activator activities, either soluble or insoluble, were almost simultaneously increased in the lung, suggesting the possible release of plasminogen-activator from the lung to the blood. It seems likely that plasminogen-activator of the usual type and nonplasmin protease are also involved in thrombotic disorders in the experimental diabetes.

“…Deposition of fibrin in compartments of the kidney with subsequent obstruction of blood vessels and uriniferous tubules occurs in various clinical syndromes, such as in acute glomerulonephritis, acute renal failure, hemolytic uremic syndrome, immunoglobu lin A nephropathy, different coagulopathies as well as in acute renal graft rejection [34][35][36][37][38]. On the other hand, fibrinolytic activity of the kidney (plasminogen dependent) or PAA is affected by several physiological or pathophysiological factors [13,21,[39][40][41], Therefore, sex-related differences in the sus ceptibility to the above pathological condi tions or to various factors affecting the renal function through the local fibrinolytic sys tem might exist.…”

Section: Discussionmentioning

confidence: 99%

Sex-Related Differences in Plasminogen Activator Activity and Plasminogen Activator Inhibition of Human and Animal Kidneys: Effect of Orchidectomy or Ovariectomy

Smokovitis

Kokolis²,

Taitzoglou³

1991

Self Cite

Plasminogen activator activity (PAA), plasminogen activator inhibition (PAI) and plasmin inhibition (PI) have been studied with spectrophotometric methods in extracts of human, bovine, ovine and rat kidneys of both sexes. In all species studied, renal PAA (cortex or medulla) was higher in females than in males. The PAA was also higher in the medulla than in the cortex in all species and both sexes. The PAA was due to both types of plasminogen activator; tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). In the human kidney (cortex or medulla) the measurement of t-PA antigen showed that t-PA is higher in females than in males; t-PA is also higher in the medulla than in the cortex in both sexes. The PAI showed the opposite pattern in all species studied; it was lower in females than in males. It was also lower in the medulla than in the cortex. PAI-1 was identified in the human kidney. Sex-related differences in renal PAA or PAI almost disappeared after bilateral orchidectomy in rats. PI showed no sex or regional differences in the species studied. Sex-related differences in renal PAA and PAI in man and various animal species might be of physiological or pathophysiological importance.